Form 4: Summit Therapeutics Co-CEO Increases Stake by $50M

Co-CEO Mahkam Zanganeh acquired 3.81 million shares of Summit Therapeutics common stock at $13.12 per share.

Summary

• Co-CEO Mahkam Zanganeh purchased 3,810,000 shares of Summit Therapeutics (SMMT) common stock.
• The transaction occurred on June 12, 2026, at a price of $13.12 per share.
• The total value of the acquisition is approximately $49,987,200.
• Following the transaction, the reporting person maintains significant beneficial ownership through various trusts and family holdings.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly bullish signal, as a $50 million personal investment by a Co-CEO indicates extreme confidence in the company's trajectory.

Positives

• Significant insider confidence demonstrated by a $50 million open-market purchase by the Co-CEO.
• Alignment of management interests with long-term shareholder value.

Negatives

• None identified in this filing.

Risks

• Concentration of ownership within the Zanganeh family entities.
• Market volatility associated with biotech equity valuations.

Future Outlook

The filing does not provide forward-looking operational guidance, but the substantial capital deployment by the Co-CEO suggests strong internal belief in the company's future prospects.

Industry Context

StockSavvy.ai notes that large-scale insider buying in the biotechnology sector is often viewed as a strong signal of confidence in upcoming clinical trial results or strategic milestones, particularly when executed by a Co-CEO.

Comparison to Industry Standards

• The scale of this purchase is significantly larger than typical executive stock acquisitions, which often involve smaller, periodic grants or modest open-market buys.
• This level of capital commitment is consistent with high-conviction leadership seen in growth-stage biotech firms.

Related Party Transactions

• The filing discloses holdings through the Mahkam Zanganeh Revocable Trust and the Shaun Zanganeh Irrevocable Trust.

Stakeholder Impact

• Positive signal for shareholders regarding management's commitment to the company's long-term success.

Next Steps

• Monitor future SEC filings for additional changes in beneficial ownership.

Key Dates

Recommendation

A $50 million open-market purchase by a Co-CEO is a rare and powerful indicator of insider confidence, suggesting that management expects significant positive developments that are not yet fully reflected in the current share price.

Keywords

Summit Therapeutics, SMMT, Insider Trading, Form 4, Biotech, Mahkam Zanganeh